Department of Kinesiology and Nutrition, College of Applied Health Sciences, University of Illinois Chicago.
Department of Physical Therapy, School of Health Professions, University of Alabama at Birmingham.
Rehabil Psychol. 2024 May;69(2):129-134. doi: 10.1037/rep0000534. Epub 2024 Jan 1.
PURPOSE/OBJECTIVE: Walking dysfunction, depression, and anxiety are prevalent, burdensome, and interrelated outcomes in persons with multiple sclerosis (MS). The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a common patient-reported outcome (PRO) of walking dysfunction in research and practice involving MS, but the construct validity of its scores might be influenced by symptoms of depression and anxiety. This study examined if symptoms of depression and anxiety influenced the construct validity of MSWS-12 scores.
RESEARCH METHOD/DESIGN: The sample included 189 participants with MS who completed the MSWS-12, Hospital Anxiety and Depression Scale (HADS-Depression subscale [HADS-D] and HADS-Anxiety subscale [HADS-A]), 6-minute walk (6MW), and timed 25-foot walk (T25FW). We conducted bivariate correlation analysis to examine the associations between MSWS-12 scores and both the 6MW and T25FW, while controlling for HADS-D and HADS-A scores.
MSWS-12 scores were significantly correlated with the 6MW ( = -.752), T25FW ( = .694), HADS-D ( = .405), and HADS-A ( = .235). The correlations between MSWS-12 and 6MW (pr = -.725) and T25FW (pr = .685) did not change when controlling for HADS-D and HADS-A scores. The correlations between MSWS-12 and 6MW ( = -.708 and = -.726) and T25FW ( = .687 and = .748) were strong in subsamples with elevated HADS-D and HADS-A scores.
CONCLUSIONS/IMPLICATIONS: Our results strengthen the validity evidence for MSWS-12 scores as a PRO of walking dysfunction in MS, including among those with symptoms of depression and anxiety. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
目的/目标:行走功能障碍、抑郁和焦虑是多发性硬化症(MS)患者中普遍存在的、负担沉重且相互关联的结果。12 项多发性硬化症行走量表(MSWS-12)是研究和实践中涉及 MS 的行走功能障碍的常见患者报告结局(PRO),但其评分的结构效度可能受到抑郁和焦虑症状的影响。本研究旨在检验抑郁和焦虑症状是否会影响 MSWS-12 评分的结构效度。
研究方法/设计:该样本包括 189 名多发性硬化症患者,他们完成了 MSWS-12、医院焦虑和抑郁量表(HADS-Depression 子量表[HADS-D]和 HADS-Anxiety 子量表[HADS-A])、6 分钟步行(6MW)和定时 25 英尺步行(T25FW)。我们进行了双变量相关分析,以检验 MSWS-12 评分与 6MW 和 T25FW 之间的关联,同时控制 HADS-D 和 HADS-A 评分。
MSWS-12 评分与 6MW(r=-.752)、T25FW(r=.694)、HADS-D(r=.405)和 HADS-A(r=.235)显著相关。控制 HADS-D 和 HADS-A 评分后,MSWS-12 与 6MW(pr=-.725)和 T25FW(pr=.685)之间的相关性并未改变。在 HADS-D 和 HADS-A 评分升高的亚组中,MSWS-12 与 6MW(r=-.708 和 r=-.726)和 T25FW(r=.687 和 r=.748)之间的相关性较强。
结论/意义:我们的研究结果加强了 MSWS-12 评分作为多发性硬化症患者行走功能障碍的 PRO 的有效性证据,包括在有抑郁和焦虑症状的患者中。(PsycInfo 数据库记录(c)2024 APA,保留所有权利)。